Recro Pharma Inc (NASDAQ:REPH) – Research analysts at Piper Jaffray Companies boosted their FY2022 earnings per share estimates for shares of Recro Pharma in a research report issued to clients and investors on Wednesday, November 7th. Piper Jaffray Companies analyst D. Amsellem now expects that the specialty pharmaceutical company will post earnings per share of $0.69 for the year, up from their prior estimate of $0.65. Piper Jaffray Companies has a “Buy” rating and a $10.00 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Wednesday, September 5th. ValuEngine cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 11th. Finally, Janney Montgomery Scott set a $13.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Monday, October 1st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $12.88.

Shares of NASDAQ REPH opened at $7.35 on Thursday. The firm has a market cap of $151.04 million, a PE ratio of -3.69 and a beta of -0.51. Recro Pharma has a twelve month low of $4.78 and a twelve month high of $13.05. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. The company had revenue of $18.28 million for the quarter, compared to analysts’ expectations of $16.77 million. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 194.05%.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Recro Pharma by 27.6% in the 2nd quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock valued at $5,747,000 after acquiring an additional 247,559 shares in the last quarter. Newtyn Management LLC acquired a new stake in Recro Pharma in the 2nd quarter valued at $4,456,000. Engine Capital Management LP increased its stake in Recro Pharma by 472.3% in the 2nd quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock valued at $1,964,000 after buying an additional 322,937 shares during the last quarter. Renaissance Technologies LLC increased its stake in Recro Pharma by 5.2% in the 2nd quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock valued at $1,914,000 after buying an additional 18,700 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Recro Pharma by 29.5% in the 3rd quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock valued at $2,063,000 after buying an additional 66,062 shares during the last quarter. 54.79% of the stock is currently owned by institutional investors and hedge funds.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Read More: Closed-End Mutual Funds (CEFs)

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.